Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial
Primary result · MMSE scoreResult — go to the resultMean difference +1.4Authors' conclusion
Choline alfoscerate 1200 mg once daily treatment showed marginal improvement in cognitive function in T2DM patients with mild cognitive impairment at 6 months but leading to significance at 12 months compared to placebo, suggesting its potential as an adjunct therapy for managing early cognitive decline.
Study context
- Population
- T2D with mild cognitive impairment (Mini-Mental State Examination (MMSE) 25–28); mean age 71.8 ± 5.3 years, 69.4% women
- Participants
- 36 participants
- Comparison
- Choline alfoscerate 1200 mg/day vs placebo
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
MMSE score · 6 months
Mean difference
+1.4
P = 0.059
By group
Choline alfoscerate
26.9
± 2.0
Placebo
25.9
± 2.3
As reported in the abstract
Further findings
| Outcome | Mean difference | P value |
|---|---|---|
| MMSE score · 12 months | +1.7 | P < 0.001 |
Physical health (SF-36)
- Physical health significantly better with choline alfoscerate than placebo
Original publication
Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial. Diabetes Obes Metab. Published 20 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →